Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (887)	7/1/1997 1:16:00 AM
From: David S.	of 6136

Just to show you that I'm nonbiased (like Walter Cronkite), I'll say that the Reuters article is a bunch of crap. I believe that June sales of Viracept could actually be higher than analyst expectations. Also, the notion that the Vertex drug could/would/should/whatever be on the market in '98 was given to me by a Vertex scientist. The real reason the stock was off today was the resignation of the director of research. The Reuters article doesn't make sense. Of course, I still say that the stock is way overvalued on fundamentals. In fact, in an earlier post when I suggested that in a best case the stock would be fairly valued at $50-60, I was being overly generous.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next